| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| AN2 Therapeutics, Inc. | Chief Strategy Officer | Common Stock | 31,914 | $610,007 | $19.11 | 15 Mar 2024 | Direct |
| AN2 Therapeutics, Inc. | Chief Strategy Officer | Stock Option (right to buy) | 60,000 | 15 Mar 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| ANTX | AN2 Therapeutics, Inc. | 15 Mar 2024 | 1 | $0 | 4/A | Chief Strategy Officer | 29 Mar 2024, 16:17 |
| ANTX | AN2 Therapeutics, Inc. | 15 Mar 2024 | 2 | $0 | 4 | Chief Strategy Officer | 18 Mar 2024, 19:28 |
| ANTX | AN2 Therapeutics, Inc. | 09 Jan 2024 | 5 | -$115,352 | 4 | Chief Strategy Officer | 11 Jan 2024, 19:59 |
| ANTX | AN2 Therapeutics, Inc. | 02 Jan 2024 | 3 | -$50,882 | 4 | Chief Strategy Officer | 04 Jan 2024, 18:06 |
| ANTX | AN2 Therapeutics, Inc. | 15 Feb 2023 | 1 | $0 | 4 | Chief Strategy Officer | 17 Feb 2023, 18:19 |
| ANTX | AN2 Therapeutics, Inc. | 12 May 2022 | 1 | $0 | 4 | Chief Strategy Officer | 16 May 2022, 21:16 |
| ANTX | AN2 Therapeutics, Inc. | 24 Mar 2022 | 0 | $0 | 3 | Chief Strategy Officer | 24 Mar 2022, 21:27 |